In this article, we will look at the 10 Oversold NYSE Stocks to Buy Now.
On August 6, Trivariate Research founder and CEO, Adam Parker, appeared on CNBC’s ‘Closing Bell’ to talk about the markets.
nasHe made the argument that dips should be bought, reasoning that most institutional investors believe we are likely to experience a growth scare, possibly a stagflation scare, from August through October.
People generally want to buy high-quality stocks if they go down 10%-15%, and he thinks that the market is not going to get a very big sell-off.
READ ALSO: 10 NYSE Stocks with the Highest Upside Potential and 10 Best Strong Buy Penny Stocks to Buy Now.
Looking at the trajectory of earnings, he believes they are higher, and he does not feel more negative about 26 or 27 earnings than he did a month ago. While markets certainly go up every day, Parker does not see a problem with valuation.
While there might be individual names with challenges, he is comfortable with the market level because he sees margins probably going up for the average company.
Parker added that he still has a “pretty solid dream” that he will get productivity for a lot of companies in the next 18 months.
With these trends in view, let’s look at the top oversold NYSE stocks to buy now.
An iconic image of a modern financial institution’s office, with prestigious experts discussing stock market fluctuations.
Our Methodology
We used stock screeners to compile a list of NYSE stocks that experienced significant YTD performance declines and selected the top 10 stocks with the highest analyst upside potential. We also added the number of hedge fund holders for each stock as of Q1 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of analyst upside potential.
Note: All data was recorded on August 6.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10 Oversold NYSE Stocks to Buy Now
10. SM Energy Company (NYSE:SM)
YTD Decline: -31.27%
Analyst Upside: 49.58%
Number of Hedge Fund Holders: 37
SM Energy Company (NYSE:SM) is one of the top oversold NYSE stocks to buy now. On August 1, analyst Gabriele Sorbara from Siebert Williams Shank & Co maintained a Buy rating on SM Energy Company (NYSE:SM), raising the price target to $43.00 from $39.00.
The analyst based the rating on SM Energy Company’s (NYSE:SM) favorable financial metrics and solid operational performance, stating that the company reported a robust quarter with oil production surpassing expectations. This positively affected key financial figures, including Free Cash Flow, EBITDA, and Discretionary Cash Flow per Share (DCFPS).
SM Energy Company (NYSE:SM) reported its fiscal Q2 2025 results on July 31, with adjusted EBITDAX for the quarter reaching $569.6 million, up $83.6 million, or 17%, from $485.9 million in the same period in 2024. The company also reported $113.9 million in adjusted free cash flow.
Sorbara added that despite a rise in capital expenditures, the lower cash taxes and increased production levels are anticipated to support these metrics further, supporting the optimistic outlook.
SM Energy Company (NYSE:SM) is an independent energy company that engages in the exploration, development, acquisition, and production of gas, oil, and natural gas liquids.
9. CBIZ, Inc. (NYSE:CBZ)
YTD Decline: -23.40%
Analyst Upside: 51.56%
Number of Hedge Fund Holders: 21
CBIZ, Inc. (NYSE:CBZ) is one of the top oversold NYSE stocks to buy now. On July 24, William Blair analyst Andrew Nicholas reiterated a bullish stance on CBIZ, Inc. (NYSE:CBZ), giving the stock a Buy rating without assigning a price target.
The analyst supported his positive rating with the company’s strategic cost management and resilience, stating that CBIZ, Inc. (NYSE:CBZ) managed to maintain its full-year guidance while battling challenges such as tariff uncertainties, geopolitical tensions, and reduced government funding.
According to the analyst, CBIZ, Inc. (NYSE:CBZ) has the potential to offset revenue pressure through solid cost control measures, including a reduction in discretionary spending and incentive compensation. This has resulted in an improvement in the company’s adjusted EPS and adjusted EBITDA margin.
CBIZ, Inc. (NYSE:CBZ) functions as a professional services advisor to middle-market businesses and organizations nationwide. The company’s services span tax, accounting, benefits, advisory, technology, and insurance. Its operations are divided into the following segments: Financial Services, Benefits and Insurance Services, and National Practices.
8. Organon & Co. (NYSE:OGN)
YTD Decline: -43.70%
Analyst Upside: 54.76%
Number of Hedge Fund Holders: 28
Organon & Co. (NYSE:OGN) is one of the top oversold NYSE stocks to buy now. Organon & Co. (NYSE:OGN) reported its fiscal Q2 2025 results on August 5, with revenue for the quarter reaching $1.594 billion and diluted earnings per share of $0.56.
GAAP diluted earnings per share for the quarter included a $46 million gain, or $0.14 per share, for early extinguishment of debt.
Organon & Co. (NYSE:OGN) reported net income of $145 million for fiscal Q1 2025, while adjusted EBITDA (non-GAAP) was $522 million, representing an adjusted EBITDA margin of 32.7%.
Management reported that Organon & Co. (NYSE:OGN) repaid $345 million of long-term debt during fiscal Q1 2025, and is on track to attain a net debt to adjusted EBITDA ratio of less than 4.0x by year-end.
The company also raised its revenue guidance range for the full year 2025 to $6.275 billion to $6.375 billion, based on its current views of foreign exchange. Organon & Co. (NYSE:OGN) affirmed the guidance range for adjusted EBITDA margin (non-GAAP) at 31.0% to 32.0%.
Organon & Co. (NYSE:OGN) is a global pharmaceutical company that develops and delivers innovative health solutions via a portfolio of prescription therapies within women’s health, established brands, and biosimilars.
7. Crescent Energy Company (NYSE:CRGY)
YTD Decline: -35.93%
Analyst Upside: 54.91%
Number of Hedge Fund Holders: 34
Crescent Energy Company (NYSE:CRGY) is one of the top oversold NYSE stocks to buy now. KeyBanc analyst Tim Rezvan reiterated a Buy rating on Crescent Energy Company (NYSE:CRGY) on August 5 without a price target.
The rating update came after Crescent Energy Company (NYSE:CRGY) reported its fiscal Q2 2025 results on August 4, exhibiting robust financial performance with all metrics surpassing expectations.
Crescent Energy Company (NYSE:CRGY) generated $499 million in operating cash flow and $171 million in levered free cash flow.
The company also drove continued operating efficiencies, improving drilling, completion, and facilities (DC&F) expenses by around 15% across South Texas and the Uinta when compared to 2024.
Management further reported that Crescent Energy Company (NYSE:CRGY) closed around a “$72 million accretive minerals acquisition” on July 31, adding “complementary assets” to its existing minerals portfolio.
Crescent Energy Company (NYSE:CRGY) is a differentiated US energy company with operations focused on Texas and the Rockies, with active development in the Eagle Ford and Uinta basins. The company is also involved in the operation of conventional assets in Wyoming, where it focuses on carbon capture, use, and storage (CCUS).
6. Civitas Resources Inc. (NYSE:CIVI)
YTD Decline: -37.80%
Analyst Upside: 61.23%
Number of Hedge Fund Holders: 41
Civitas Resources Inc. (NYSE:CIVI) is one of the top oversold NYSE stocks to buy now. Mizuho Securities analyst Nitin Kumar CFA maintained a Buy rating on Civitas Resources Inc. (NYSE:CIVI) on July 9, setting a price target of $50.00.
Civitas Resources Inc. (NYSE:CIVI) reported in its fiscal Q1 2025 earnings that it returned $121 million to shareholders, including $50 million in dividends and $71 million in share repurchases.
The company also announced the launch of a $100-plus million cost optimization and efficiency initiative, with savings anticipated to come from production optimization, capital efficiencies, streamlined corporate costs, and commercial/midstream opportunities.
Civitas Resources Inc. (NYSE:CIVI) expects around $40 million to benefit 2025 free cash flow, with the entire amount additive to 2026.
Civitas Resources Inc. (NYSE:CIVI) is an independent exploration and production company that acquires, develops, and produces crude oil and associated liquids-rich natural gas. Its operations take place primarily in the Denver-Julesburg Basin in Colorado and the Permian Basin in Texas and New Mexico.
5. Novo Nordisk A/S (NYSE:NVO)
YTD Decline: -45.11%
Analyst Upside: 63.48%
Number of Hedge Fund Holders: 60
Novo Nordisk A/S (NYSE:NVO) is one of the top oversold NYSE stocks to buy now. In a report released on August 4, Emily Field from Barclays maintained a Hold rating on Novo Nordisk A/S (NYSE:NVO), with a price target of DKK375.00.
In other news, Novo Nordisk A/S (NYSE:NVO) announced on August 5 the filing of 14 new lawsuits against vendors selling cheaper compounded versions of its medication semaglutide, which is marketed as the blockbuster Wegovy for obesity.
The announcement came one day after the digital weight-loss company Noom’s launch of low-dose copies of semaglutide at a considerable discount to the branded product in a market that the telehealth company Hims & Hers Health dominates.
Novo Nordisk A/S’s (NYSE:NVO) U.S. head of operations, Dave Moore, stated that:
“No one should have to gamble with their health by using knockoff drugs made with ingredients that lack oversight and safety standards. We urge regulators to enforce laws designed to protect public health.”
Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products.
Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.
4. Inspire Medical Systems, Inc. (NYSE:INSP)
YTD Decline: -52.58%
Analyst Upside: 70.63%
Number of Hedge Fund Holders: 37
Inspire Medical Systems, Inc. (NYSE:INSP) is one of the top oversold NYSE stocks to buy now. Robert W. Baird analyst David Rescott maintained a Buy rating on Inspire Medical Systems, Inc. (NYSE:INSP) on August 5, setting a price target of $150.00.
The rating update came after Inspire Medical Systems, Inc.’s (NYSE:INSP) release of its fiscal Q2 2025 earnings on August 4.
Inspire Medical Systems, Inc. (NYSE:INSP) generated $217.1 million in revenue in fiscal Q2 2025, reflecting an 11% rise over the same quarter last year. Gross margin for the quarter reached 84.0%, while net loss was $3.6 million.
The company reported $13.3 million in adjusted net income, while adjusted diluted earnings per share were $0.45 for fiscal Q2 2025.
Inspire Medical Systems, Inc. (NYSE:INSP) also announced the initiation of the full launch of the Inspire V neurostimulation system in the United States.
Inspire Medical Systems, Inc. (NYSE:INSP) is a medical technology company that develops and commercializes innovative, minimally invasive solutions for obstructive sleep apnea.
The company offers Inspire therapy, which includes implantable components with a pressure-sensing lead, a stimulation lead, and a neurostimulator, operable through a remote control.
3. Clearwater Analytics Holdings, Inc. (NYSE:CWAN)
YTD Decline: -25.91%
Analyst Upside: 71.65%
Number of Hedge Fund Holders: 41
Clearwater Analytics Holdings, Inc. (NYSE:CWAN) is one of the top oversold NYSE stocks to buy now. On July 20, RBC Capital analyst Rishi Jaluria maintained a Buy rating on Clearwater Analytics Holdings, Inc. (NYSE:CWAN) and set a price target of $36.00.
Clearwater Analytics Holdings, Inc. (NYSE:CWAN) reported record quarterly revenue of $126.9 million in fiscal Q1 2025, up 24% year-over-year. Annualized recurring revenue for the quarter also rose 23% year-over-year to $493.9 million, while net income reached $6.9 million.
Management reported a gross revenue retention rate of 98%, while the net revenue retention rate for fiscal Q1 2025 was 114%.
Clearwater Analytics Holdings, Inc. (NYSE:CWAN) also announced a 40% year-over-year increase in adjusted EBITDA for the quarter, reaching $45.1 million.
Clearwater Analytics Holdings, Inc. (NYSE:CWAN) provides web-based investment portfolio accounting, reporting, and reconciliation services. The company’s operations are divided into the United States and the Rest of the World geographical segments.
2. BellRing Brands, Inc. (NYSE:BRBR)
YTD Decline: -51.98%
Analyst Upside: 93.48%
Number of Hedge Fund Holders: 43
BellRing Brands, Inc. (NYSE:BRBR) is one of the top oversold NYSE stocks to buy now. William Blair analyst Jon Andersen maintained a bullish stance on BellRing Brands, Inc. (NYSE:BRBR) on August 5, giving the stock a Buy rating without assigning a price target.
The analyst supported the optimistic rating with BellRing Brands, Inc.’s (NYSE:BRBR) strong financial performance in fiscal Q3 2025, with EBITDA surpassing both the firm’s and market expectations.
According to the analyst, this suggests solid earnings quality with increased sales and gross margins, supported by a higher-than-expected operating expense ratio.
The analyst added that management provided a more focused full-year earnings and sales guidance for BellRing Brands, Inc. (NYSE:BRBR), which reflects increased optimism and confidence in the company’s operational strategy.
BellRing Brands, Inc. (NYSE:BRBR) is a consumer product holding company that provides ready-to-drink (RTD) protein shakes, powders, nutrition bars, and other RTD beverages. Its primary brands are Dymatize and Premier Protein.
1. Alight Inc. (NYSE:ALIT)
YTD Decline: -39.45%
Analyst Upside: 102.86%
Number of Hedge Fund Holders: 41
Alight Inc. (NYSE:ALIT) is one of the top oversold NYSE stocks to buy now. Alight Inc. (NYSE:ALIT) reported its fiscal Q2 2025 results on August 5, with revenue for the quarter decreasing 1.9% to $528 million, compared to $538 million in the prior year period.
Management attributed the drop to lower net commercial activity and project revenue. Recurring revenues made up 93.2% of total revenue.
Alight Inc. (NYSE:ALIT) also reported $176 million in gross profit, which translates to 33.3% of revenue, compared to $167 million, or 31.0% of revenue, in the prior year period.
The company stated that this change in gross profit was primarily due to productivity savings. Adjusted EBITDA for fiscal Q2 2025 improved to $127 million from $105 million in fiscal Q2 2024.
Alight Inc. (NYSE:ALIT) reported several new wins or expanded relationships in the quarter, with companies including Thermo Fisher Scientific, Reinsurance Group of America, Highmark Health, and Incorporated (RGA) and Trinity Industries.
It repurchased $20 million of common stock under the existing share repurchase program, and declared and paid a $0.04 per share dividend.
Headquartered in Chicago, IL, Alight Inc. (NYSE:ALIT) provides cloud-based integrated digital human capital and business solutions.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
Hedge Fund Resource Center